Fezolinetant is the first Neurokinin 3 receptor antagonist to be licensed in the UK.
Its an oral tablet which helps manage flushes and sweats, the commonest menopause symptoms, by altering brain neurotransmitter levels. Because its non-hormonal, it can be an option for women who cannot or don't want to take HRT.
Fezolinetant has been available on private prescription since mid-January 2024
at a cost of about £45-50 per month (not including pharmacy dispensing fee).
My patients who have started using it have found it very helpful.
Treatment requires monitoring with regular liver function tests before starting and, in January 2025, the manufacturer has recommended monthly liver function tests for the first 3 months of treatment.
Commentaires